Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds ...
Q4 2025. Management View. Stacy Lindborg (President, CEO & Director) said the company entered 2026 “with strong momentum” and highlighted ...
2d
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data GuidancePhase 1b/2 NMIBC Trial on Track: ...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...
5h
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today ...
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI ...
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs ...
Base outlines its 2026 roadmap focused on global markets, stablecoins, and builders as it expands its onchain economy ...
Three undervalued Dividend Aristocrats we identified a year ago have delivered positive returns since. Three new picks also ...
Dr. Jennifer Buell (President, CEO & Director) reiterated MiNK’s differentiation as “an off the shelf” allogeneic iNKT platform that is “administered without lymphodepletion, without HLA matching,” ...
ALPENA — Alpena Public Schools hosted a second “Reimagine our Future” community forum on Tuesday night, when representatives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results